Pathophysiology and effects of endogenous glucocorticoid (GC) excess on skeletal endpoints as well as awareness and management of bone fragility are reviewed. Cushing's syndrome (CS) increase the risk of fracture affecting prevalently bone quality. Bone antiresorptive agents (SERMs, bisphosphonates and denosumab) as well as teriparatide increase bone mineral density and in some instances reduce fracture risk. Awareness and management of bone health in CS can be improved.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.beem.2021.101515 | DOI Listing |
Publication Analysis
Top Keywords
cushing's syndrome
8
awareness management
8
management bone
8
bone
5
osteopathy mild
4
mild adrenal
4
adrenal cushing's
4
syndrome cushing
4
cushing disease
4
disease pathophysiology
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!